EP2655663A4 - Biomarker und ihre verwendung für prognose- und behandlungsstrategien für rechtsseitiges und linksseitiges kolonkarzinom - Google Patents

Biomarker und ihre verwendung für prognose- und behandlungsstrategien für rechtsseitiges und linksseitiges kolonkarzinom

Info

Publication number
EP2655663A4
EP2655663A4 EP11850360.6A EP11850360A EP2655663A4 EP 2655663 A4 EP2655663 A4 EP 2655663A4 EP 11850360 A EP11850360 A EP 11850360A EP 2655663 A4 EP2655663 A4 EP 2655663A4
Authority
EP
European Patent Office
Prior art keywords
cancer
biomarkers
prognosis
strategies
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11850360.6A
Other languages
English (en)
French (fr)
Other versions
EP2655663A2 (de
Inventor
Steven Buechler
Amanda B Hummon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Notre Dame
Original Assignee
University of Notre Dame
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Notre Dame filed Critical University of Notre Dame
Publication of EP2655663A2 publication Critical patent/EP2655663A2/de
Publication of EP2655663A4 publication Critical patent/EP2655663A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y106/00Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/03Oxidoreductases acting on NADH or NADPH (1.6) with oxygen as acceptor (1.6.3)
    • C12Y106/03001NAD(P)H oxidase (1.6.3.1), i.e. NOX1
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP11850360.6A 2010-12-20 2011-12-20 Biomarker und ihre verwendung für prognose- und behandlungsstrategien für rechtsseitiges und linksseitiges kolonkarzinom Withdrawn EP2655663A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061459864P 2010-12-20 2010-12-20
PCT/US2011/066233 WO2012088146A2 (en) 2010-12-20 2011-12-20 Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease

Publications (2)

Publication Number Publication Date
EP2655663A2 EP2655663A2 (de) 2013-10-30
EP2655663A4 true EP2655663A4 (de) 2015-01-28

Family

ID=46314850

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11850360.6A Withdrawn EP2655663A4 (de) 2010-12-20 2011-12-20 Biomarker und ihre verwendung für prognose- und behandlungsstrategien für rechtsseitiges und linksseitiges kolonkarzinom

Country Status (2)

Country Link
EP (1) EP2655663A4 (de)
WO (1) WO2012088146A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2821507A1 (de) * 2013-07-01 2015-01-07 Centre National de la Recherche Scientifique (CNRS) Verfahren zur Erkennung, Identifizierung und/oder Quantifizierung eines Pathogens in einem Individuum
CN114540499A (zh) * 2022-03-17 2022-05-27 郑州源创吉因实业有限公司 基于pcd相关基因组合构建的模型在制备预测结肠腺癌预后产品中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355149A2 (de) * 2002-03-29 2003-10-22 Ortho-Clinical Diagnostics, Inc. Bewertung von kolorektalem Krebs
WO2005010486A2 (en) * 2003-07-18 2005-02-03 Lee Nancy M Biomarker panel for colorectal cancer
WO2010132817A1 (en) * 2009-05-14 2010-11-18 Cancer Prevention Pharmaceuticals, Llc Carcinoma diagnosis and treatments, based on odc1 genotype

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919061B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355149A2 (de) * 2002-03-29 2003-10-22 Ortho-Clinical Diagnostics, Inc. Bewertung von kolorektalem Krebs
WO2005010486A2 (en) * 2003-07-18 2005-02-03 Lee Nancy M Biomarker panel for colorectal cancer
WO2010132817A1 (en) * 2009-05-14 2010-11-18 Cancer Prevention Pharmaceuticals, Llc Carcinoma diagnosis and treatments, based on odc1 genotype

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012088146A2 *
VINCENT JAQUET ET AL: "FORUM REVIEW ARTICLE Small-Molecule NOX Inhibitors: ROS-Generating NADPH Oxidases as Therapeutic Targets Introduction: NOX Enzymes and Their Distribution/Regulation", ANTIOXIDANTS AND REDOX SIGNALING, 1 October 2009 (2009-10-01), pages 2535 - 2552, XP055212413, Retrieved from the Internet <URL:http://online.liebertpub.com/doi/pdf/10.1089/ars.2009.2585> [retrieved on 20150910] *

Also Published As

Publication number Publication date
WO2012088146A2 (en) 2012-06-28
WO2012088146A3 (en) 2012-10-11
EP2655663A2 (de) 2013-10-30

Similar Documents

Publication Publication Date Title
PL3296319T3 (pl) Sposoby leczenia nowotworu jelita grubego
EP2603622A4 (de) Biomarker für bauchspeicheldrüsenkrebs und verwendungen davon
EP2872144A4 (de) Irak-inhibitor und verwendungen davon
SI2619576T1 (sl) Sredstva in metode za predvidevanje odziva rakavega pacienta na zdravljenje
EP2756093A4 (de) C10rf32-antikörper und verwendungen davon zur behandlung von krebs
EP2771692A4 (de) Biomarker für lungenkrebs und verwendung
DK2868102T3 (da) Tiles og wavefront front parallel processering
EP2744830A4 (de) Lsr-antikörper und verwendungen davon zur behandlung von krebs
EP2972308A4 (de) Biomarker und verfahren zur vorhersage einer frühgeburt
BR112014007603A2 (pt) métodos de tratamento do câncer
EP2938459A4 (de) Teilchenförmige materialien und verfahren zur herstellung davon
EP2925888A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP2575804A4 (de) Verfahren zur behandlung von pankreaskrebs
LT2707030T (lt) Vėžio gydymas
EP2805167A4 (de) Biomarker für magenkrebs und verwendungen davon
PL2550294T3 (pl) Profilaktyka nowotworu jelita grubego i nowotworu przewodu pokarmowego
HRP20181462T1 (hr) Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
HRP20181576T8 (hr) Blok za dijagnosticiranje transakcije
BR112012002571A2 (pt) tratamento de minérios de titânio
EP2672970A4 (de) Formen von rifaximin und anwendungen davon
EP2714023A4 (de) Vernetzte polymer-nanobaugruppen und verwendungen davon
BR112013011659A2 (pt) métodos de tratamento do câncer
BR112014011008A2 (pt) método de quantificação de tratamento de câncer
EP2903605A4 (de) Angiotensin zur behandlung von hirnzuständen
PL2742356T3 (pl) Środki prognostyczne w leczeniu nowotworów

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130722

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20150107

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/574 20060101ALI20141219BHEP

Ipc: C12N 15/113 20100101ALI20141219BHEP

Ipc: C12N 15/11 20060101ALI20141219BHEP

Ipc: C12Q 1/68 20060101AFI20141219BHEP

17Q First examination report despatched

Effective date: 20150915

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190103